Dexcom | DXCM - Equity Capital And Reserves


Dexcom reported $2.96B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Align Technology USD 4.15B 100.27M Mar/2026
AtriCure USD 491.69M 242K Mar/2026
Avanos Medical USD 782.1M 3.9M Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Becton, Dickinson and Co. USD 24.13B 1.15B Mar/2026
Boston Scientific USD 25.86B 1.63B Mar/2026
Cooper Companies USD 8.36B 124.7M Dec/2025
Dexcom USD 2.96B 210.9M Mar/2026
Edwards Lifesciences USD 10.33B 10.1M Mar/2026
Globus Medical USD 4.73B 159.06M Mar/2026
Inogen USD 197.18M 2.32M Sep/2025
Insulet USD 1.3B 212.6M Mar/2026
Integra LifeSciences USD 1.04B 1.06M Mar/2026
J&J USD 81.19B 358M Mar/2026
Masimo USD 788.9M 67.7M Mar/2026
Medtronic USD 48.99B 128M Dec/2025
Merit Medical Systems USD 1.63B 42.42M Mar/2026
Roche Holding CHF 33.8B 758M Dec/2025
Solventum Corp USD 4.97B 80M Mar/2026
Stryker USD 22.42B 635M Dec/2025
Tandem Diabetes Care USD 132.4M 22.77M Mar/2026
Teleflex USD 3.08B 40.33M Mar/2026
West Pharmaceutical Services USD 2.99B 185.6M Mar/2026
Zimmer Biomet Holdings USD 12.68B 16.1M Mar/2026